Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Sep 16 2016

• By Joseph Haas

chess

Related Content

FDA Dispute Resolution Process Invoked About 10 Times Annually

Aug 17 2012

FDA Latest Opioid Dilemma: Can Apadaz Stop Snorting Abuse – And Does That Even Matter?

May 04 2016

KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim

May 06 2016

Dispute Resolution Strategies: FDA Clarifies Which Issues Can Be Appealed

Sep 21 2015

If At First You Don’t Succeed, Try Dispute Resolution

Dec 09 2013

Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?

Jun 14 2016

Related Companies

Zevra Therapeutics, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Regulation Drug Approval Standards Drug Review Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window